A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)....
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy....
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic P...
A Randomized Multicenter Study for Isolated Skin Vasculitis
Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis....
Abatacept for the Treatment of Giant Cell Arteritis
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing G...
Iptacopan in Patients With ANCA Associated Vasculitis
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with ...
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis....
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV....
Top Cities for Vasculitis Clinical Trials
Vasculitis clinical trials are recruiting across 55 cities. Here are the cities with the most active studies:
About Vasculitis
Vasculitis refers to a group of disorders that involve inflammation of blood vessels, which can restrict blood flow and damage organs. Types include ANCA-associated vasculitis, giant cell arteritis, and Takayasu arteritis. Treatment typically involves corticosteroids and immunosuppressive medications.
Clinical trials are advancing new treatments for vasculitis. Currently, 8 studies are recruiting a combined 897 participants across the United States. Research is being conducted by 5 organizations including Amgen, GlaxoSmithKline, Novartis Pharmaceuticals and 2 others.
2026 Vasculitis Research Landscape
As of March 2026, the vasculitis clinical trial landscape includes 8 actively recruiting studies across 55 cities in the United States. These studies are collectively seeking 897 participants, with an average enrollment target of 112 per study.
Research is being led by 5 different organizations, including Amgen, GlaxoSmithKline, Novartis Pharmaceuticals, University of Pennsylvania, NS Pharma, Inc..
Geographically, vasculitis trials are most concentrated in Rochester, Minnesota (5 trials); New York, New York (4 trials); Philadelphia, Pennsylvania (4 trials); Nashville, Tennessee (4 trials); Cleveland, Ohio (4 trials) and 7 other cities.
Featured Vasculitis Studies
Highlighted recruiting studies for vasculitis, selected by enrollment size and research scope.
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Frequently Asked Questions About Vasculitis Clinical Trials
Are there vasculitis clinical trials near me?
Yes, there are 8 vasculitis clinical trials currently recruiting across 55+ cities in the United States, including Rochester, Minnesota; New York, New York; Philadelphia, Pennsylvania. Browse the studies above to find one at a location convenient for you.
How do I join a vasculitis clinical trial?
To join a vasculitis clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are vasculitis clinical trials free?
Yes, participation in vasculitis clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of vasculitis treatments are being studied?
Current vasculitis clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 5 research organizations.
Is it safe to participate in vasculitis clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov